Tag Archives: Wegovy: Genetic profile may predict best response to weight-loss drug

Certain genes may identify patients with obesity who are most likely to respond strongly to Novo Nordisk’s weight-loss drug Wegovy, researchers reported on Monday. The study, released at the Digestive Disease Week meeting in Washington, found a 95% likelihood that patients with this genetic profile would be strong responders to the treatment. Given the expense of Wegovy, the findings might …

Read More »